Kurt Fernstrom

Array ( [id] => 19457698 [patent_doc_number] => 12098178 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-09-24 [patent_title] => Methods of using interleukin-2 agents [patent_app_type] => utility [patent_app_number] => 17/541989 [patent_app_country] => US [patent_app_date] => 2021-12-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 54 [patent_figures_cnt] => 80 [patent_no_of_words] => 102311 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17541989 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17945764 [patent_doc_number] => 20220332781 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-20 [patent_title] => GLUCAGON-RECEPTOR SELECTIVE POLYPEPTIDES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/538507 [patent_app_country] => US [patent_app_date] => 2021-11-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38927 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17538507 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17520516 [patent_doc_number] => 20220106365 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-07 [patent_title] => PROTEINS FOR THE TREATMENT OF EPITHELIAL BARRIER FUNCTION DISORDERS [patent_app_type] => utility [patent_app_number] => 17/526970 [patent_app_country] => US [patent_app_date] => 2021-11-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36844 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17526970 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17702890 [patent_doc_number] => 20220202896 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-30 [patent_title] => COMPOSITION FOR CONTROLLED RELEASE OF THERAPEUTIC AGENTS [patent_app_type] => utility [patent_app_number] => 17/519378 [patent_app_country] => US [patent_app_date] => 2021-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9862 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17519378 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17792071 [patent_doc_number] => 20220251162 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-11 [patent_title] => PAC1 RECEPTOR AGONISTS (MAXCAPS) AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/510090 [patent_app_country] => US [patent_app_date] => 2021-10-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19325 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17510090 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17355458 [patent_doc_number] => 20220016254 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-20 [patent_title] => CONJUGATES OF FUSION PROTEINS OF GLP-1 AND FGF21 [patent_app_type] => utility [patent_app_number] => 17/485424 [patent_app_country] => US [patent_app_date] => 2021-09-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27800 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17485424 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17576984 [patent_doc_number] => 20220133839 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-05 [patent_title] => PEPTIDE ANALOGUES WITH BRANCHED AMINO ACID PROBE(S) [patent_app_type] => utility [patent_app_number] => 17/470310 [patent_app_country] => US [patent_app_date] => 2021-09-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20426 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17470310 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18289916 [patent_doc_number] => 11618779 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-04-04 [patent_title] => Cartilage replacement compositions and methods [patent_app_type] => utility [patent_app_number] => 17/410212 [patent_app_country] => US [patent_app_date] => 2021-08-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 7 [patent_no_of_words] => 4811 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17410212 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17604026 [patent_doc_number] => 11332497 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-05-17 [patent_title] => Therapeutic peptides [patent_app_type] => utility [patent_app_number] => 17/393944 [patent_app_country] => US [patent_app_date] => 2021-08-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51377 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 117 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17393944 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18368143 [patent_doc_number] => 11648291 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-05-16 [patent_title] => Method of using PRD, PRD-S TAD, ZF7 peptide or mixture thereof to inhibit cellular response to inflammatory stimuli or treat cytokine-storm-mediated diseases [patent_app_type] => utility [patent_app_number] => 17/391063 [patent_app_country] => US [patent_app_date] => 2021-08-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 25 [patent_no_of_words] => 6991 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17391063 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17385589 [patent_doc_number] => 20220033441 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-03 [patent_title] => LAG3 Binding Peptides [patent_app_type] => utility [patent_app_number] => 17/386637 [patent_app_country] => US [patent_app_date] => 2021-07-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7422 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17386637 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17126210 [patent_doc_number] => 20210300978 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-30 [patent_title] => DELIVERY OF NRF2 AS THERAPY FOR PROTECTION AGAINST REACTIVE OXYGEN SPECIES [patent_app_type] => utility [patent_app_number] => 17/342120 [patent_app_country] => US [patent_app_date] => 2021-06-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21325 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17342120 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17272991 [patent_doc_number] => 20210379189 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-09 [patent_title] => Immunomodulatory Compounds [patent_app_type] => utility [patent_app_number] => 17/337489 [patent_app_country] => US [patent_app_date] => 2021-06-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7348 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 188 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17337489 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17563185 [patent_doc_number] => 20220127334 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-28 [patent_title] => UTI FUSION PROTEINS [patent_app_type] => utility [patent_app_number] => 17/337922 [patent_app_country] => US [patent_app_date] => 2021-06-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12107 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17337922 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17095430 [patent_doc_number] => 20210283221 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-16 [patent_title] => Ornithodoros Moubata Complement Inhibitor for Use in the treatment of Complement-Mediated Diseases in Patients with C5 Polymorphism [patent_app_type] => utility [patent_app_number] => 17/333675 [patent_app_country] => US [patent_app_date] => 2021-05-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13323 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17333675 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17741456 [patent_doc_number] => 11389501 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2022-07-19 [patent_title] => Method for treating eye inflammation using anti-inflammatory composition having bioactive compound [patent_app_type] => utility [patent_app_number] => 17/329169 [patent_app_country] => US [patent_app_date] => 2021-05-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 5453 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17329169 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19441450 [patent_doc_number] => 12091692 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-09-17 [patent_title] => PH20 polypeptide variants, formulations and uses thereof [patent_app_type] => utility [patent_app_number] => 17/327568 [patent_app_country] => US [patent_app_date] => 2021-05-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 145207 [patent_no_of_claims] => 40 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 134 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17327568 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17154914 [patent_doc_number] => 20210315965 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-14 [patent_title] => ABC TRANSPORTER PEPTIDE INHIBITOR XH-14C AND APPLICATION THEREOF [patent_app_type] => utility [patent_app_number] => 17/324063 [patent_app_country] => US [patent_app_date] => 2021-05-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5558 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17324063 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18028947 [patent_doc_number] => 11512120 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-11-29 [patent_title] => Antimicrobial peptide Scyreprocin of [patent_app_type] => utility [patent_app_number] => 17/230243 [patent_app_country] => US [patent_app_date] => 2021-04-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 8 [patent_no_of_words] => 4707 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 114 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17230243 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17235575 [patent_doc_number] => 11179438 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2021-11-23 [patent_title] => Chicken cathelicidins as a cancer therapy [patent_app_type] => utility [patent_app_number] => 17/210726 [patent_app_country] => US [patent_app_date] => 2021-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 22 [patent_no_of_words] => 15322 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17210726 [rel_patent_id] =>[rel_patent_doc_number] =>)